Immunogenicity of a peptide from a major neutralising determinant of the feline immunodeficiency virus surface glycoprotein

Vaccine

Volumn 14, Issue 12, 1996, Pages 1095-1102

  Rigby, Mark A ^a   Mackay, Nancy ^a   Reid, George ^a,b   Osborne, Robert ^a   Neil, James C ^a   Jarrett, Oswald ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

Feline immunodeficiency virus; Peptide vaccine

Indexed keywords

IMMUNOLOGICAL ADJUVANT; PEPTIDE; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAT; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FELINE IMMUNODEFICIENCY VIRUS; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; SHEEP; VACCINATION;

EID: 0030581357     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(96)00060-6     Document Type: Article

References (42)

1. 1 Pederson, N.N., Ho, E.W. and Yamamoto, J. Isolation of a T-lymphotrophic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987, 235, 790-793
2. 2 Torten, M., Franchini, M., Barlough, J.E. et al. Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus. J. Virol. 1991, 65, 2225-2230
3. 3 Gardner, M.B. Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents. Antiviral Res. 1991, 15, 267-286
4. 4 Jarrett, O., Neil, J.C. and Yamamoto, J.K. Feline immunodeficiency virus as a model for AIDS vaccination. AIDS 1990, 4suppl. 1, S163-S165
5. 5 Yamamoto, J.K., Okuda, T., Ackley, C.D. et al. Experimental vaccine protection against feline immunodeficiency virus. AIDS Res. Human Retroviruses 1991, 7, 911-921
6. 6 Hosie, M.J., Osborne, R., Yamamoto, J.K., Neil, J.C. and Jarrett, O. Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines. J. Virol. 1995, 69, 1253-1255
7. 7 Hohdatsu, T., Pu, R., Torres, B.A., Trujillo, S., Gardner, M.B. and Yamamoto, J.K. Passive antibody protection of cats against feline immunodeficiency virus infection. J. Virol. 1993, 67, 2344-2348
8. 8 Tozzini, F., Matteucci, D., Bandecchi, P. et al. Simple in vitro methods for titrating feline immunodeficiency virus (FIV) and FIV neutralising antibodies. J. Virol. Meth. 1992, 37, 241-252
9. 9 Osborne, R., Rigby, M.A., Siebelink, K., Neil, J.C. and Jarrett, O. Virus neutralisation reveals antigenic variation among feline immunodeficiency virus isolates. J. Gen. Virol. 1994, 75, 3641-3645
10. 10 Leonard, C.K., Spellman, M.W., Harris, R.J., Thomas, J.N. and Gregory, TJ. Assignment of intrachain disulphide bonds and characterisation of potential glycosylation sites of the type I recombinant human immunodeficiency virus envelope glycoprotein (gp120) produced in Chinese Hamster Ovary cells. J. biol. Chem. 1990, 265, 10373-10382
11. 11 Goudsmit, J., Debouch, C., Meloen, R.H. et al. Human immunodeficiency virus type 1 neutralisation epitope with conserved architecture elicits early type-specific antibodies in experimetally infected chimpanzees. Proc. natn Acad. Sci. USA 1988, 85, 4478-4482
12. 12 Palker, T.J., Clark, M.E., Langlois, A.J. et al. Type specific neutralisation of the human immunodeficiency virus with antibodies to env encoded synthetic peptides. Proc. natn Acad. Sci. USA-1988, 85, 1932-1936
13. 13 Putney, S.D., Matthews, T.J., Robey, W.G. et at. HTLV-III/LAV-neutralising antibodies to an E. coli produced fragment of the virus envelope. Science 1986, 234, 1392-1395
14. 14 Rusche, J.R., Javaherian, K., McDanal, C. et al. Antibodies that inhibit fusion of human immunodeficiency virus infected cells bind a 24 amino acid sequence of the viral envelope, gp120. Proc. natn Acad. Sci. USA 1988, 85, 3198-3202
15. 15 Nehete, P.N., Arlinghaus, R.B. and Sastry, K.J. Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120. J. Virol. 1993, 67, 6841-6846
16. 16 Emini, E.A., Schleif, W.A., Nunberg, J.H. et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992, 355, 728-730
17. 17 Gorny, M.K., Conley, A.J., Karwowska, S. et al. Neutralisation of diverse HIV-1 variants by an anti-V3 human monoclonal antibody. J. Virol. 1992, 66, 7538-7542
18. 18 Javaherian, K., Langlois, A.J., LaRosa, G.J. et al. Broadly neutralising antibodies elicited by the hypervariable neutralising determinant of HIV-1. Science 1990, 250, 1590-1593
19. 19 Javaherian, K., Langlois, A.J., Schmidt, S. et al. The principal neutralisation determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus. Proc. natn Acad. Sci. USA 1992, 89, 1418-1422
20. 20 Pancino, G., Chappey, C., Saurin, W. and Sonigo, P. B epitopes and selection pressures in feline immunodeficiency virus envelope glycoproteins. J. Virol. 1993, 67, 664-672
21. 21 Lombardi, S., Garzelli, C., La Rosa, C. et al. Identification of a linear neutralisation site within the third variable region of the feline immunodeficiency virus envelope. J. Virol. 1993, 67, 4742-4749
22. 22 De Ronde, A., Stam, J.G., Boers, P. et al. Antibody response in cats to the envelope proteins of feline immunodeficiency virus: identification of an immunodominant neutralisation domain. Virology 1994, 198, 257-264
23. 23 Lombardi, S., Garzelli, C., Pistello, M. et al. A neutralising antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. J. Virol. 1994, 68, 8374-8379
24. 24 Genetics Computer Group. Programme Manual for the GCG Package, version 7, April 1991. Genetics Computer Group, Madison, WI
25. 25 Devereux, J., Haeberli, P. and Smithies, O. A comprehensive set of sequence analysis programs for the VAX. Nucl. Acids Res. 1984, 12, 387-395
26. 26 Rigby, M.A., Holmes, E.C., Pistello, M., Mackay, A., Leigh Brown, A.J. and Neil, J.C. Evolution of structural proteins of feline immunodeficiency virus: molecular epidemiology and evidence of selection for change. J. Gen. Virol. 1993, 74, 425-436
27. 27 Reid, G., Rigby, M.A., McDonald, M., Hosie, M.J., Neil, J.C. and Jarrett, O. lmmunodiagnosis of feline immunodeficiency virus infection using recombinant viral p17 and p24. AIDS 1991, 5, 1477-1483
28. 28 Olmsted, R.A., Hirsch, V.M., Purcell, R.H. and Johnson, P.R. Nucleotide sequence analysis of feline immunodeficiency virus: genome organisation and relationship to other lentiviruses. Proc. natn Acad. Sci. USA 1989, 86, 8088-8092
29. 29 Garnier, J., Osguthorpe, D.J. and Robson, B. Analysis of the accuracy and implications pf simple methods for predicting the secondary structure of globular proteins. J. molec. Biol. 1978, 120, 97-120
30. 30 La Rosa, G.J., Davide, J.P., Weinhold, K. et al. Conserved sequence and structural elements in the HIV-1 principle neutralising determinant. Science 1990, 249, 932-935
31. 31 Flynn, J.N., Cannon, C.A., Reid, G., Rigby, M.A., Neil, J.C. and Jarrett, O. Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunisation with a multiple antigenic peptide from the envelope V3 domain. Immunology 1995, 85, 171-175
32. 32 Skinner, M.A., Langlois, A.J., McDanal, C.B., McDougal, J.S., Bolognesi, D.P. and Matthews, T.J. Neutralising antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J. Virol. 1991, 62, 4195-4200
33. 33 Hwang, S.S., Boyle, T.J., Lyerly, H.K. and Cullen, B.R. Identification of the envelope V3 loop as the primary determainant of cell tropism in HIV-1. Science 1991, 253, 71-74
34. 34 Siebelink, K.H.J., Karlas, J.A., Rimmelzwaan, G.F., Osterhaus, A.D.M.E. and Bosch, M.L. A determinant of feline immunodeficiency virus involved in Crandell feline kidney cell tropism. Vet. Immun. Immunopath. 1995, 46, 61-69
35. 35 Verschoor, E.J., Boven, L.A., Blaak, H., van Vliet, A.L.W., Horzinek, M.C. and de Ronde, A. A single mutation within the V3 envelope neutralisation domain of feline immunodeficiency virus determines its tropism for CrFK cells. J. Virol. 1995, 69, 4752-4757
36. 36 Weijer, K., Pfauth, A. and van Herwijnen, R. Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene. Vaccine 1993, 11, 946-956
37. 37 Hosie, M.J., Dunsford, T.H., de Ronde, A. et al. Suppression of virus burden by immunisation with feline immunodeficiency virus Env protein. Vaccine 1996, 14, 405-411
38. 38 Baldinotti, F., Matteucci, D., Mazzetti, P. et al. Serum neutralisation of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. J. Virol. 1994, 68, 4572-4579
39. 39 Beebe, A.M., Dua, N., Faith, T.G., Moore, P.F., Pedersen, N.C. and Dandekar, S. Primary stage of feline immunodeficiency virus infection: viral dissemination and cellular targets. J. Virol. 1994, 68, 3080-3091
40. 40 Walker, M.C., Fast, P.E., Graham, B.S., Belshe, R. and Dolin, R. Phase I/II preventive vaccine trials: conference summary. AIDS Res. Human Retroviruses 1995, 11, 1279-1285
41. 41 Rubinstein, A., Goldstein, H., Pettoello-Mantovani, M. et al. Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivatives in HIV-seronegative volunteers. AIDS 1995, 9, 243-251
42. 42 Conley, A.J., Canard, P., Bondy, S. et al. Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens. Vaccine 1994, 12, 445-451